Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cytolex MSI-78 1 percent topical antibiotic cream data

MAGN announced results of its second pivotal Phase III equivalence trial of Cytolex (MSI-78) to treat infection of diabetic foot ulcers. The results

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE